There is one clinical trial.
A study in healthy subjects to investigate the safety and tolerability of ACT-541478 as well
as what ACT-541478 does to the body and the way the body takes up, distributes, and gets rid
of of ACT-541478
Primary Outcomes
Measure: Treatment-emergent (serious) AEs Time: From (first) study treatment administration up to 96 h after last study treatment administration in the corresponding period (if applicable). Total duration: up to 5 days.
Other Outcomes
Measure: Plasma PK parameters of ACT-541478 - Part A and B, incl. A3 (fed condition): Cmax Time: Blood samples for PK analysis will be taken at various timepoints. Total duration: up to 5 days.
Measure: Plasma PK parameters of ACT-541478 - Part A and B, incl. A3 (fed condition): tmax Time: Blood samples for PK analysis will be taken at various timepoints. Total duration: up to 5 days.
Measure: Plasma PK parameters of ACT-541478 - Part A and B, incl. A3 (fed condition): AUC0-inf Time: Blood samples for PK analysis will be taken at various timepoints. Total duration: up to 5 days.
Measure: Plasma PK parameters of ACT-541478 - Part A and B, incl. A3 (fed condition): t½ Time: Blood samples for PK analysis will be taken at various timepoints. Total duration: up to 5 days.
Measure: Plasma PK parameters of ACT-541478 - Part C, incl. C1 to C3 (adults) and E1 (elderly): Cmax Time: Blood samples for PK analysis will be taken at various timepoints. Total duration: up to 5 days.
Measure: Plasma PK parameters of ACT-541478 - Part C, incl. C1 to C3 (adults) and E1 (elderly): tmax Time: Blood samples for PK analysis will be taken at various timepoints. Total duration: up to 5 days.
Measure: Plasma PK parameters of ACT-541478 - Part C, incl. C1 to C3 (adults) and E1 (elderly): AUCτ Time: Blood samples for PK analysis will be taken at various timepoints. Total duration: up to 5 days.
Measure: Plasma PK parameters of ACT-541478 - Part C, incl. C1 to C3 (adults) and E1 (elderly): t1/2 Time: Blood samples for PK analysis will be taken at various timepoints. Total duration: up to 5 days.
Measure: Specific/additional parameters related to safety and tolerability - Part B Time: At various timepoints. Total duration: up to 5 days.